NCT00969527

Efficacy of Oncoxin Plus Viusid in the Treatment of Rheumatoid Arthritis

Assessment of the Efficacy of Oncoxin+Viusid Administration in the Treatment of Rheumatoid Arthritis

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 86 (actual)
• Sponsor: Catalysis SL · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of the study is to assess the efficacy of Oncoxin+Viusid administration in the treatment of rheumatoid arthritis. The duration of this double-blind placebo controlled phase 3 clinical trial will be 12 weeks. The estimated number of persons with rheumatoid arthritis to be recruited and randomized for the study is 86. The primary outcome measure: DAS28 score will be assessed at the end of the study.

Conditions

• Rheumatoid Arthritis

Interventions

Type	Name	Description
DIETARY_SUPPLEMENT	Oncoxin + Viusid	50 ml of Oncoxin + Viusid (Orally administered) twice a day, for 12 weeks.
DIETARY_SUPPLEMENT	Placebo	50 ml of Placebo (orally administered) twice a day, for 12 weeks.

Timeline

• Start date: 2009-09-01
• Primary completion: 2011-03-01
• Completion: 2011-04-01
• First posted: 2009-09-01
• Last updated: 2011-05-09

Locations

1 site across 1 country: Cuba